No retraction, correction or concern found when last checked on Oct 19, 2026.

Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance

Chongbing Liao, Xin Huang, Qingxia Wang and 2 more

Frontiers in Cellular and Infection Microbiology · 2022 · Review · CC BY

doi:10.3389/fcimb.2022.926758

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen causing nosocomial infections in severely ill and immunocompromised patients. Ubiquitously disseminated in the environment, especially in hospitals, it has become a major threat to human health due to the constant emergence of drug-resistant strains. Multiple resistance mechanisms are exploited by P. aeruginosa , which usually result in chronic infections difficult to eradicate. Diverse virulence factors responsible for bacterial adhesion and colonization, host immune suppression, and immune escape, play important roles in the pathogenic process of P. aeruginosa . As such, antivirulence treatment that aims at reducing virulence while sparing the bacterium for its eventual elimination by the immune system, or combination therapies, has significant advantages over traditional antibiotic therapy, as the former imposes minimal selective pressure on P. aeruginosa , thus less likely to induce drug resistance. In this review, we will discuss the virulence factors of P. aeruginosa , their pathogenic roles, and recent advances in antivirulence drug discovery for the treatment of P. aeruginosa infections.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

1 Introduction

1Pseudomonas aeruginosa is a Gram-negative bacterium widely distributed in the environment, usually inhabiting soil, water, plants and humans. It is also an environmentally resilient microorganism that can grow in nutrient-deficient conditions and live in a broad temperature range from 4 to 42°C. The tenacious adaptability and survivability of P. aeruginosa allows itself to survive on dry, abiotic surfaces in hospitals for up to 6 months. As one of the main causative agents of opportunistic nosocomial infections, P. aeruginosa primarily infects the gravely ill or immunocompromised patients, especially those with severe burn/surgery wounds, cancer or AIDS. In fact, hospital-acquired P. aeruginosa causes dermatitis, bacteremia, and infections of the respiratory and urinary tracts and of other vital organs, accounting for 10-20% nosocomial cases and 50% fatality.

2Frequent occurrence of drug resistance and persistent colonization on humid surfaces makes P. aeruginosa particularly difficult to treat and eradicate. Multiple intrinsic and acquired resistant mechanisms are exploited by P. aeruginosa, including but not limited to inactivation of antibiotics, modification of drug targets, attenuation of membrane permeability, expression of efflux systems, formation of biofilms and quorum-sensing, which, collectively, contribute to its distinctly low antibiotic susceptibility. As a member of the life-threatening “ESKAPE bugs” (standing for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) known for their increasing prevalence of drug resistance and bacterial virulence, P. aeruginosa is designated by World Health Organization as a top antibiotic-resistant “priority pathogen” for which new antibiotics are critically required.

3Therapies targeting bacterial virulence are an effective approach to alleviating growing bacterial resistance to traditional antibiotics that aim to either kill bacteria or inhibit their growth. Antivirulence strategies focus on neutralizing bacterial virulence factors and reducing bacterial infectivity without direct killing of the bacteria. Consequently, there is less selective pressure on the survival of bacteria, thus less likely to induce drug resistance. P. aeruginosa is armed with a variety of virulence factors, such as flagella, pilli and LPS that contribute to bacterial adhesion/colonization to the host, secretion systems that deliver effectors and toxins into the host, proteases and toxins that cause tissue damage, and quorum-sensing and biofilm that confer bacterial communication and drug resistance. A considerable number of antivirulence drug candidates against P. aeruginosa are in preclinical and clinical trials, including antibodies, small molecule inhibitors and alginate oligomers. This review summarizes the virulence factors of P. aeruginosa and their pathogenic mechanisms, followed by discussions of various antivirulence strategies to fend off P. aeruginosa infections.

2 The Virulence Factors of P. Aeruginosa

4The virulence of pathogens entails their ability to infect the host and to cause clinical symptoms through factors that contribute to bacterial attachment to and colonization and invasion of the host, interruption of host tissue integration, suppression of and escape from host immune response, and depletion of nutrients from the host. Successful antivirulence therapy requires a full understanding of bacterial virulence factors and their pathogenic mechanisms so that appropriate drugs can be developed for infection treatment. The virulence factors of P. aeruginosa have been thoroughly studied and are classified differently in various literatures. For clarity and a better readership, we divide them into three main categories, namely bacterial surface structures, secreted factors and bacterial cell-to-cell interaction, which can be further divided into several subclasses as shown in Figure 1 and Table 1.

2.1.1 Surface Appendages

5Type IV pili of P. aeruginosa is a motorized fimbriae composed of repeated copies of a 15-kDa protein termed pilin, with three subtypes named Type IVa pili, Type IVb pili and Type IVb-Tad pili. It is associated with bacterial twitching and swarming motility and adhesion on various surfaces, and plays an important role in biofilm formation, regulation of virulence factors, and bacterial exchange of antibiotic resistance genes. Repeated extension and retraction of type IV pili are driven by cytoplasmic ATPases, facilitating bacterial motility, taxis, and attachment, which in turn contribute to self-organization of microcolonies, formation of biofilms, and uptake of DNAs. As an important adhesin, type IV pili also enables bacteria to be in intimate contact with surfaces and to influence biofilm formation by regulating cyclic-di-GMP levels.

6Flagella of P. aeruginosa are hairlike appendages protruding from the bacterial surface, mainly comprising the protein subunits called flagellin. As a motility apparatus that enables bacterial movement and chemotaxis, flagella contribute to bacterial adhesion via flagellin and the flagellar cap protein FliD, and promote biofilm maturation of P. aeruginosa. Flagella can elicit activation of host immune response through Toll-like receptor 5 (TLR5), and are highly immunogenic. Therefore, vaccination with flagellar-antigen preparations and a cocktail vaccine including flagellin B has successfully elicited protective immunity in mouse models.

2.1.2 Outer Membrane Components

7Lipopolysaccharide (LPS) is a major component of the outer membrane in Gram-negative bacteria, and can be found in all P. aeruginosa strains. Composed of lipid A moiety, inner and outer core oligosaccharides, as well as the O-antigen, LPS may be the most extensively studied bacterial molecule due to its high immunogenicity and surface accessibility. As a microbe-associated molecular pattern (MAMP), LPS can be a potent activator of host immune response via various signal transduction pathways including toll-like receptor 4 (TLR4) and the cystic fibrosis transmembrane conductance regulator (CFTR). Paradoxically, LPS can stimulate neutrophils to release neutrophil extracellular traps (NETs) to capture invading pathogens, but protect bacteria from phagocytosis. The interaction between LPS and eukaryotic cells contributes to the adherence of P. aeruginosa to the host. Of note, even though various LPS-targeted vaccines have been created against P. aeruginosa with encouraging results, most of them failed to show satisfactory efficacy.

2.1.3 Secretion Systems

8Type 1 secretion system (T1SS) is one of the simplest secretion systems in Gram-negative bacteria that plays an active virulent role during the inflammatory phase in P. aeruginosa infection process. There exist two types of T1SS in P. aeruginosa, Apr T1SS and HasF T1SS. The Apr T1SS consists of AprD, AprE, and AprF, and is involved in the secretion of alkaline proteases AprA and AprX; the HasF T1SS, composed of HasD, HasE, and HasF, is involved in the secretion of heme acquisition protein HasAp as well as utilization of iron (; Wandersman and Delepelaire, 2004; ).

9Type 2 secretion system (T2SS) of P. aeruginosa secretes major extracellular toxins that possess diverse activities associated with the infection of patients with potential respiratory diseases. In P. aeruginosa, two T2SS’s have been characterized, Xcp T2SS and Hxc T2SS. While the former secretes numerous exoproteins that participate in the bacterial infection process, including Exotoxin A (PEA), Protease IV, Elastase A and B (LasA and LasB), Lipase A and C (LipA and LipC), and Phospholipase C (PLC), the latter only secretes the low molecular weight alkaline phosphatases, LapA and LapB, that contribute to extracellular alkaline phosphatase activity under phosphate-limiting conditions.

10Type 3 secretion system (T3SS), composed of the needle complex, effectors, chaperones and regulation proteins, is one of the most important virulence factors of P. aeruginosa. The needle complex is formed by a basal body, a needle filament and a translocon, which protrudes from the bacterial surface to act as a “molecular syringe” to inject effector proteins of P. aeruginosa into host cells that come in contact. The basal body of the needle complex consists of ATPase complex, cytoplasmic ring (C ring), export apparatus and the cytoplasmic base, whereas the needle filament is formed by multiple copies of a protein termed PscF; the translocon is composed of two pore-forming proteins (termed PopB and PopD) and the needle-pore bridge PcrV. The effectors are commonly injected into host cells by the T3SS to initiate bacterial invasion and exert cytotoxicity. ExoS, ExoT, ExoU, and ExoY are four well-studied T3SS effectors of P. aeruginosa, while the other two, PemA and PemB, still remain obscure. T3SS chaperones are proteins facilitating secretion or assembly of their cognate partners such as effectors and structural proteins of the T3SS. Proteins that regulate the secretion process are mostly transcriptional modulators, secretion or traffic regulators, and chaperones.

11The T3SS enables P. aeruginosa to invade and infect the host and promotes pathogenicity. It is directly related to the clinical manifestations and severity of infections, and acts as a key factor of bacterial virulence. Mutations in T3SS effectors can reduce or abolish bacterial virulence; the lethality of P. aeruginosa in patients infected by strains lacking PcrV is greatly reduced, compared with those possessing PcrV. The close association of the T3SS with the severity of clinical infections makes it one of the most extensively studied virulence factors of P. aeruginosa, and certainly one of the most promising therapeutic targets for antivirulence drug discovery and development.

12Type 5 secretion system (T5SS) is the simplest secretion system of P. aeruginosa, which can be divided into autotransporters (AT) and a two-partner secretion system. The T5SS secretes a variety of proteins related to bacterial virulence and adhesion, including EstA, TpsA and TpsB. EstA can increase the expression of rhamnolipid and, subsequently, promote biofilm formation; TpsA and TpsB are two β-barrel outer membrane exoproteins that mainly secrete large virulence proteins (>100 kDa), participate in immune escape, and enhance bacterial adhesion. In addition, autotransport proteases, as one of the main secretions of the T5SS, plays a crucial role in nutrient acquisition. AaaA, for example, is such an autotransport protease involved in nitrogen acquisition of peptides in chronic infections.

13Type 6 secretion system (T6SS) is a versatile secretion system where three independent T6SS hemolysin coregulated protein (Hcp) secretion islands (H1-, H2- and H3-T6SS) have been characterized in P. aeruginosa. The bacteriolytic effectors Tse1-3 secreted by H1-T6SS can hydrolyze the peptidoglycan cell wall of competing bacteria, while the effectors PldA and PldB of H2- and H3-T6SS can promote bacterial endocytosis into host cells via the PI3K/Akt pathway.

2.2.1 Exopolysaccharides

14Exopolysaccharides are sugar-based extracellular macromolecules secreted by P. aeruginosa to enhance bacterial tolerance to harsh survival environments such as desiccation, oxidizing agents, and host defense. As one of the main compositions of extracellular polymeric substances essential for the functional and structural integrity of biofilms, exopolysaccharides are important for P. aeruginosa in biofilm formation, and can also act as adhesins contributing to bacterial persistence in patients. At present, alginate, Psl and Pel are three exopolysaccharides discovered in P. aeruginosa. Alginate is generally secreted by the strains isolated from cystic fibrosis patients, while Psl and Pel are mainly produced by the strains obtained from the environment. Although the mechanisms of their action remain poorly understood, the antibodies targeting alginate or Psl have been developed for antivirulence therapy.

2.2.2 Siderophores

15Siderophores are iron-chelating compounds secreted by the bacteria to help with iron accumulation. Two siderophores are produced by P. aeruginosa: the fluorescent high-affinity peptidic pyoverdine (Pvd) and pyochelin (Pch) with a relatively lower affinity. Pvd and Pch can chelate irons, especially Fe3+, from transferrin and lactoferrin to promote bacterial growth, and are both required for full virulence of P. aeruginosa. Despite being of low-affinity for irons, pyochelin can be produced by the bacteria in place of pyoverdine, even in the presence of strong iron chelators, indicative its indispensable role in the iron niche of Pseudomonas aeruginosa.

2.2.3 Proteases

16Alkaline protease (AprA) is a virulence factor secreted by type I secretion system and controlled by the quorum-sensing circuit. AprA can degrade complement components, as well as IFN-γ and TNF-α, thereby counteracting host immune defense and exacerbating infections in the body. Elastase A and B (LasA and LasB) are produced by P. aeruginosa to destroy elastin, an important component of the pulmonary tissue and blood vessels, impairing lung function and causing pulmonary hemorrhage. Protease IV is significantly associated with corneal virulence of P. aeruginosa. Not only can protease IV interfere with host immunity by degrading various biologically important molecules, such as complement components, immunoglobulins, and surfactant proteins, but also damage host tissues and enhance bacterial infection through degradation of fibrinogen, lactoferrin, transferrin, and elastin. Since protease IV is a serine protease, known serine protease inhibitors that block its enzymatic activity may be developed into therapeutics to prevent tissue damage caused by P. aeruginosa infection.

2.2.4 Toxins

17The four effectors secreted by the T3SS, namely ExoS, ExoT, ExoU, and ExoY, are commonly referred to as the toxins of P. aeruginosa. ExoS and ExoT, sharing a 76% sequence similarity, are both bifunctional cytotoxins with GTPase activating protein (GAP) activity and adenosine diphosphate ribosyl transferase (ADPRT) activity. They can disrupt the host actin cytoskeleton to interfere with cell-to-cell adhesion, and induce apoptosis of host cells. ExoU is a potent phospholipase and the most virulent T3SS effector that causes rapid necrotic cell death. Notably, ExoU and ExoS almost never co-exist in one strain. ExoY can be classified as an adenylate or nucleotidyl cyclase that significantly increases the levels of cAMP, cGMP, cUMP and, to a lesser extent, cCMP. Found in over 90% analyzed isolates, ExoT and ExoY are the two most frequent T3SS effectors in P. aeruginosa. While the strains expressing ExoS are closely related to poor prognosis of infected patients, strains expressing ExoU are usually more resistant to antibiotics.

18Exolysin (ExlA) is a pore-forming toxin identified from the P. aeruginosa clinical isolate CLJ1 that lacks a T3SS locus. ExlA is encoded by an exclusive two-gene genetic element——exlA-exlB, and displays cytolysin activity. ExlA induces plasma membrane permeabilization, resulting in necrotic cell death, a process dependent on the type IV pili for bacterial adhesion (; Pauline et al., 2017).

19Extoxin A of P. aeruginosa (PEA) is one of the most toxic exocellular factors secreted by the T2SS under regulation by iron and glycose metabolisms (;; Abdelali et al., 2014). PEA inhibits host protein synthesis by catalyzing the ADP ribosylation of cell elongation factor 2 (EF-2) and induces programmed cell death.

20Lipase A (LipA) is the major extracellular lipase secreted by P. aeruginosa type II secretion system. It can wreak havoc on tissues by degrading the major lung surfactant lipid dipalmitoylphosphatidylcholine as well as host cell membranes. In addition, studies have shown that LipA interacts with alginate in the extracellular biofilm matrix produced by P. aeruginosa itself through electrostatic interactions, contributing to bacterial drug resistance.

21Phospholipase C (PLC) is produced by P. aeruginosa in two forms: hemolytic and non-hemolytic. Several studies have shown that hemolytic PLC can induce host vascular permeability, organ damage and cell death. Low concentrations of hemolytic PLC can increase IL-8 expression, and cause excessive neutrophil recruitment involved in pulmonary inflammation and tissue destruction. In addition, hemolytic PLC inhibits neutrophil respiratory burst by interfering with a protein kinase C (PKC)-specific, non-p38 kinase-dependent signaling pathway, contributing to P. aeruginosa survival in an immune environment rich in neutrophils and, thus, chronic bacterial infection. Published animal studies have shown that inhibition of hemolytic PLC affords a significant protective effect on the function of P. aeruginosa-infected lungs.

22Lipoxygenase (LoxA), a lipoxygenase secreted by P. aeruginosa, can interfere with host lipid signaling and regulate the bacterial invasion process. During P. aeruginosa infection of the lung, LoxA oxidizes a variety of host polyunsaturated fatty acids, and produces lipid peroxidative mediators such as lipoxin A4, resulting in host cell death. LoxA also inhibits the expression of major chemokines such as MIP and KC and the subsequent recruitment of immune cells. Inhibiting the activity of LoxA may help alleviate the severity of P. aeruginosa infection.

23Leukocidin is also a virulence factor secreted by P. aeruginosa, which is cytotoxic to leukocytes in the host immune system. Specifically, leukocidin can cause swelling of leukocytes via increased permeability of the plasma membrane, and attenuate immune function, thereby contributing to the infection of the host by P. aeruginosa.

24Pyocyanin (PCN) is a blue secondary metabolite with redox activity found in sputum from P. aeruginosa infected lungs. The zwitterionic characteristic of PCN facilitates its entry into the cytoplasmic membrane of the host, where the oxidative stress induced by PCN contributes to its cytotoxicity to host cells.

2.3.1 Quorum-Sensing

25Quorum sensing (QS) is a bacterial cell-to-cell communication system, in which the bacteria recognize the self-secreted small signal molecules called autoinducers, coordinate expression of multiple genes involved in bacterial community behaviors, virulence, and biofilm formation. Four QS pathways exist in P. aeruginosa, which are las, rhl, iqs, and pqs, utilizing respectively four autoinducers, namely N-(3-oxododecanoyl) -l-HSL (OdDHL), N-butanoyl-L-homoserine lactone (C4-HSL), 2-(2-hydroxyphenyl) -thiazole-4-carbaldehyde (IQS), and 2-heptyl-3-hydroxy-4(1H)-quinolone (PQS). Under certain conditions with adequate bacterial density, the autoinducers will be produced and combine with their receptors to control the transcription of related toxicity genes. QS plays a key role in the virulence of P. aeruginosa, such as regulating the release of multiple virulence factors (including elastase, alkaline protease, exotoxin A, rhamnolipids, pyocyanin and lipase) and promoting the maturation of biofilm as shown by Figure 2.

2.3.2 Biofilm

26Biofilm is the specific aggregated forms of bacteria encased in extracellular polymeric substances (EPS), which can help pathogenic bacteria sidestep unfavorable conditions such as temperature fluctuation, nutrient deficiency and antibiotics killing, while increasing bacterial persistency on biotic and abiotic surfaces. The ability of biofilm formation is the most significant hallmark of P. aeruginosa, and the highly structured biofilms can usually be found in chronically infected patients. Biofilm development is complicated and multiregulated, in which QS plays an essential role and its related virulence factors (such as LipA and LipC) can increase thickness and robustness of biofilms.

3 Current Antivirulence Strategies to Combat P. Aeruginosa

27Despite the large number of different types of virulence factors exploited by P. aeruginosa, screening for suitable antivirulence therapeutic targets is somehow challenging, which necessitates a clear understanding of the pathogenic mechanisms of this bacterium. The pathogenesis of P. aeruginosa has been extensively studied. In fact, this Gram-negative bacterium is generally referred to as a model pathogen for drug development targeting conserved virulence factors, such as T3SS, quorum sensing and biofilm formation. In addition, some virulence factors unique to P. aeruginosa, such as siderophores, specific proteases and exopolysaccharide, are also used as targets for the development of drugs for P. aeruginosa. Further, there are some drugs under development that target the bacterial surface structures such as flagella and LPS. These antivirulence therapeutics aim to interrupt the pathways critical for pathogenesis but not essential for bacterial growth by adopting the following strategies: interfering with the expression of bacterial virulence factors, neutralizing existing toxins, inhibiting quorum sensing and biofilm formation, and preventing bacterial attachment to and invasion of the host.

28Current antivirulence drug candidates can be classified into the categories of antibodies, small molecules, polypeptides and others. The antibodies can be fully structured monoclonal antibodies, modified bispecific antibodies, or immunoglobulin preparations; the small molecules are usually screened from libraries of natural products or synthetic chemicals; the polypeptides are mostly antibiotics that tend to kill the bacteria as exemplified by colistin and Murepavadin; chitosan and alginate oligomers encompass other class of potential drugs. We searched the clinical trial database related to P. aeruginosa on ClinicalTrial.gov and preclinical studies on PubMed. On the basis of drug targets, the representative drug candidates for antivirulence therapy listed in Table 2 are classified into 5 types: (1) disrupting T3SS function, (2) inhibiting quorum sensing and biofilm formation, (3) neutralizing secreted virulence factors, (4) targeting other bacterial surface structures, and (5) modulating bacterial metabolisms.

3.1 Disrupting T3SS Functions

29Among the five secretion systems discovered in P. aeruginosa, the T3SS is regarded as the most relevant to human pathogenesis. Since the T3SS exists in most gram-negative pathogens such as Pseudomonas, Shigella, Salmonella, Escherichia coli, Vibrio, Yersinia, and etc, antivirulence drugs targeting the T3SS have the potential to be effective against various pathogenic bacteria. The current drug candidates targeting the T3SS are primarily modified antibodies and screened/designed small molecules.

30MEDI3902 (BiS4αPa) is a bivalent human immunoglobulin IgG1κ monoclonal antibody that bi-specifically targets PcrV and Psl of P. aeruginosa. PcrV is one of the major components of T3SS translocation apparatus, located at the T3SS needle tip, and acts as the bridge between the needle and the pore on the host cell membrane triggered by the T3SS. PcrV facilitates injection of T3SS effectors into the host, and its deprivation causes loss of virulence in P. aeruginosa. Psl, as one of the main structural components of P. aeruginosa biofilms, is a mannose- and galactose-rich exopolysaccharide that plays an important role in bacterial attachment to the host. Targeting both PcrV and Psl by MEDI3902 remarkably reduced P. aeruginosa infection in animal models. Although a Phase 1 clinical trial in healthy subjects confirmed the safety and efficacy of MEDI3902, results from a Phase 2 study were unsatisfactory (NCT02696902). Another antibody-derived drug candidate KB001-A, a recombinant, PEGylated Fab targeting PcrV, also showed ineffectiveness in phase 1 and 2 clinical studies despite its safety record.

31Aside from antibodies, several small molecule candidates were developed for antivirulence therapy of P. aeruginosa. Fluorothiazinon (FT), a T3SS inhibitor derived from 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones, inhibits secretion of T3SS effectors ExoT and ExoY and protects mice from P. aeruginosa infections, and is currently in a phase 2 clinical trial (NCT03638830). However, the specific target of FT in P. aeruginosa T3SS remains unclear, and its mechanism of action warrants further investigation. INP1855, a hydroxyquinoline, reduces mortality of mice infected by P. aeruginosa by possibly targeting PscN, an ATPase of the T3SS involved in recruitment and secretion of various effectors, and flagella that mediate cytotoxicity. More detailed mechanistic studies are needed confirm its mode of action.

32We recently developed a fluorescence-polarization-based, high-throughput screening strategy for antivirulence drug discovery targeting the T3SS. Dhydrotanshinone (dHTSN) and dihydrotanshinone 1 (dHTSN1), derivatives of a subset of natural herbal compounds termed tanshinones used for the treatment of cardiovascular and cerebrovascular diseases in traditional Chinese medicine, were discovered and validated to be host protective against P. aeruginosa. These tanshinone derivatives reduced T3SS effector secretion, alleviated cytotoxicity to macrophages, and rescued mice from lethal doses of P. aeruginosa infection in the lungs. The T3SS needle protein PscF is hydrophobic and highly prone to aggregation on its own. To prevent its premature degradation and ensure its proper translocation and needle assemly, the two bacterial chaperone proteins PscE and PscG associate into a dimer to sequester the nonpolar segments of PscF, forming a druggable trimeric structure. It is this PscF-PscE-PscG trimer that we used as a target for the screening of compound libraries, leading to the discovery of dHTSN and dHTSN1 as competitive inhibitors of PscF binding to PscE-PscG complex, or inhibitors of T3SS needle biogenesis ( Figure 3 ). Due to a proven safety track record of tanshinones in clinical use, these T3SS needle assembly inhibitors may have great potential in the therapy of P. aeruginosa-associated pulmonary infections, particularly those caused by antibiotic resistant strains.

3.2 Inhibiting Quorum Sensing and Biofilm Formation

33Quorum sensing (QS) and biofilm formation are two complicated processes influenced by a variety of bacterial physiological activities. Biofilm formation contributes to bacterial persistency and resistance and is the consequence of multiple processes including, but not limited to, QS. Inhibition of QS or biofilm formation can significantly attenuate bacterial virulence, which makes them potential targets for antivirulence therapy. Efficacy of current drug candidates targeting QS or biofilm formation of P. aeruginosa, mostly small molecules screened from chemical libraries or FDA-approved compounds, has been verified in animal models or in clinical trials.

34Two candidates, M34 and Clofoctol, act as inhibitors of the pqs pathway, and suppress expression of pqs-related virulence traits in P. aeruginosa. The compound M34 was identified in a whole-cell high-throughput screen, where the pqsA-sacB and the pqsA-GFP bacterial strains were constructed for a readout that suppressed pqsA expression, and further optimized through a structure-activity relationship analysis. M34 and its derivatives possibly target the transcription factor PqsR, inhibit PQS-pqsR binding, block the synthesis of pqs-dependent signaling molecules, and protect mice from P. aeruginosa infection. Clofoctol, previously used in the treatment of infections by Gram-positive bacteria, is selected from a library of FDA-approved compounds; it inhibits the pqs system and reduces mortality of G. mellonella larvae infected by P. aeruginosa by possibly targeting PqsR as M34.

35Furanone C-30, a synthetic derivative of furanones that were originally discovered in natural food, interferes with the las pathway via binding to the transcription receptor LasR, inhibits virulence factor expression, and increases bacterial susceptibility of P. aeruginosa biofilms to tobramycin. However, several clinical P. aeruginosa isolates with mexR and nalC mutations are resistant to QS inhibitory activity of furanone C-30. Two screened synthetic compounds, MHY1383 and MHY1387, can inhibit QS virulence by competitive activities interrupting the interaction between OdHSL and LasR, while potently suppressing the biofilm formation of P. aeruginosa via reducing intracellular c-di-GMP levels.

36Meta-bromo-thiolactone (mBTL) is a novel synthetic molecule designed as an inhibitor of LasR and RhlR, and inhibits both production of the virulence factor pyocyanin and biofilm formation in P. aeruginosa. Nitric oxide (NO), a common signaling molecule, can lower the level of c-di-GMP, a key regulator of P. aeruginosa biofilm formation and bacteria dispersal; results from a completed phase 2 study of NO have yet to be reported. OligoG CF-5/20 is an alginate oligomer derived from the seaweed Laminaria hyperborean, which inhibits P. aeruginosa biofilm formation via disruption of NDA-Ca2+-DNA bridges and biofilm exopolysaccharide matrix. Several clinical trials of OligoG CF-5/20 in different stages are either completed without published data or still ongoing. AR-501, the inhaled gallium citrate that acts as iron analog to starve bacteria, inhibits biofilm formation of P. aeruginosa; the Phase 1 and 2 study of this candidate is also ongoing (Woo et al., 2019).

3.3 Neutralizing Secreted Virulence Factors

37Many virulence factors function after their secretion by P. aeruginosa. Notable examples include siderophores, protease, exopolysaccharide, and toxins. Much work aiming to neutralize secreted virulence factors focuses on siderophores, protease, and exopolysaccharide. Pyoverdine is an iron-scavenging siderophore of P. aeruginosa that ensures bacterial iron acquisition in the host, contributes to expression of different virulence factors, and is toxic itself. Three small molecule compounds, LK11, LK31, and LK31a, were discovered as pyoverdine inhibitors that protected, as bona fide antivirulence molecules, C. elegans from P. aeruginosa infection. LasB is an extracellular collagenase elastase. As a major virulence factor of P. aeruginosa, it cleaves host tissue components such as elastin or collagen, disrupts cell-to-cell junctions, and causes tissue damages. The mercaptoacetamide-based compounds, phendione and its iron complexes, were proven to be effective LasB inhibitors that prolonged survival of P. aeruginosa-infected G. mellonella larvae. Alginate, produced by P. aeruginosa strains isolated from cystic fibrosis (CF) patients with chronic pulmonary infections, plays an important role in the pathology of CF disease by contributing to bacterial adhesion and biofilm formation. Ebselen and its analogues can inhibit production of alginate by P. aeruginosa through covalent modification of Alg44, which interrupts the interaction between Alg44 and c-di-GMP. Notably, AR-105 is a broadly active human monoclonal antibody against P. aeruginosa alginate, and can protect mice from lethal challenges of P. aeruginosa. However, a Phase 2 clinical trial of AR-105 failed to demonstrate its efficacy compared with a placebo.

3.4 Targeting Other Bacterial Surface Structures

38Aside from the T3SS, other bacterial surface structures such as flagella, pili and lipopolysaccharide (LPS) are also virulence determinants of P. aeruginosa responsible for host infection involving motility, attachment, and induction of inflammation, thus potential targets for antivirulence therapy. KBPA-101 is a human monoclonal antibody against the LPS O-polysaccharide moiety of P. aeruginosa serotype IATS O11, affording full protection of mice infected by P. aeruginosa at low doses (< 5 μg/mouse). While the safety of KBPA-101 in humans has been confirmed in a Phase 1 trial, results from a Phase 2 study have yet to be published. Of note, KBPA-101 exclusively binds to the O11 serotype of P. aeruginosa isolates only, which may limit its broad clinical use. Anti-Pseudomonas IgY obtained from the yolk of the immunized hens’ egg prevented adhesion of P. aeruginosa to the host by targeting the flagellin. Although a Phase 1 study has validated the feasibility of using IgY as a treatment option, the status of its Phase 2 and 3 trials remains unclear.

3.5 Modulating Bacterial Metabolism

39The virulence factors of P. aeruginosa are implicated in bacterial metabolism. For example, quorum sensing has four related transcriptional pathways; siderophores, toxins, and proteases are all regulated by bacterial transcriptional systems that are triggered by different signal molecules. Therefore, targeting pathways involved in bacterial metabolism often produces various comprehensive effects that can be taken advantage of in a potential antivirulence therapy. Cysteamine, a simple aminothiol and an FDA-approved therapeutic for cystinosis, blocked glycine utilization of P. aeruginosa, subsequently impaired chemotaxis, reduced virulence factor production, and alleviated infection of P. aeruginosa in a G. mellonella model. Polyphosphate kinase (PPK) is critical for P. aeruginosa biofilm formation, quorum-sensing response, and virulence in the host. Gallein is a polyhydroxylated small molecule that inhibits both PPK1 and PPK2 enzymes, which in turn suppresses P. aeruginosa biofilm formation and virulence in C. elegans.

4 Potentials and Challenges

40Antivirulence drugs target specific virulence pathways instead of direct killing the bacteria, thus imposing less selective pressure and less likely to induce drug resistance. Since the bacteria treated with antivirulence drugs are still viable, the host commensal flora may remain intact. Although the host immune system is expected to clear the pathogen, it may fail to completely eliminate it, in which case a combination therapy involving antibiotics may still be required for preventing infection recurrence, improving therapeutic efficacy, and achieving bacterial eradication.

41Certain inhibitors of quorum sensing and bacterial metabolism may inhibit the production of multiple virulence factors, yet off-target effects may occur when it comes to pathway or metabolism inhibitors, resulting in unexpected side effects. The leading virulence factors may vary in different infection stages of P. aeruginosa: when the infection of a CF patient transits from acute to chronic, virulence factors like the flagellum, T3SS and proteases are down-regulated, and virulence factors as exopolysaccharides are up-regulated. A deep understanding of pathogenic mechanisms of the bacterial virulence factors is essential for antivirulence therapy so that the targets can be properly selected.

42Antivirulence therapy can target one specific pathogen or multiple bacteria. Some virulence factors are only present in a specific strain, other conserved virulence factors such as the T3SS are more broadly distributed among different bacteria. For example, the T3SS inhibitor fluorothiazinon has proved to be effective against Chlamydia spp., P. aeruginosa, A. baumannii and Salmonella sp. in vitro and in vivo. The strain specificity may require antivirulence therapy in combination with other classes of therapeutics in the circumstances of multiple bacterial infections or one bacterium with multiple virulence factors.

5 Conclusion

43Although the virulence factors of P. aeruginosa are abundant and diverse, much of the current studies on antivirulence therapy focuses on T3SS, quorum sensing and biofilm formation. While other targets include secreted siderophores, proteases and exopolysaccharide, less common are bacterial surface structures such as LPS and flagella, as well as bacterial metabolic pathways. T3SS, quorum sensing and biofilm are ubiquitous in a variety of pathogenic bacteria as relatively conserved virulence factors. Focused efforts on them may lead to effective antivirulence drugs for a variety of pathogenic bacteria. A number of virulence factors of P. aeruginosa have garnered limited attention as potential drug targets, including secretion systems other than T3SS. The exploration of more antivirulence targets for therapy obviously requires in-depth studies of their pathogenic mechanisms by which they operate in P. aeruginosa infection.

44Various drug candidates have been evaluated for their antivirulence effects on P. aeruginosa infection. Most of them are small molecules derived from chemical libraries via high-throughput screening, repurposed drugs, and natural compounds, supplemented by several engineered antibodies, then alginate oligomers. Thus far, a majority of the clinical trials documented have failed to achieve desired therapeutic effects, and no drug candidate for antivirulence therapy of P. aeruginosa has been approved or licensed for clinical use. Currently, only three drug candidates are undergoing clinical trials, while many more are in preclinical stages. With the emergence of more and more antibiotic resistant strains, antivirulence therapy will likely become an important alternative, worthy of more extensive and intensive research.

Author Contributions

45CL, XH, and WL contributed to initial conceptualization of the review. CL, XH, QW and DY performed initial literature reviews and manuscript drafting. CL and WL contributed to literature review and extensive manuscript editing. All authors contributed to the article and approved the submitted version.

Funding

46This work was financially supported by National Natural Science Foundation of China (NSFC 82030062) and China Postdoctoral Science Foundation (2021M690666).

Conflict of Interest

47The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

48All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 194

1.
Agnello M. Finkel S. E. Wong-Beringer A. (2016 ). Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas Aeruginosa Differs by Type III Secretion Genotype. Front. Microbiol. 7
Not in our library10.3389/fmicb.2016.01591
2.
Agnello M. Wong-Beringer A. (2012 ). Differentiation in Quinolone Resistance by Virulence Genotype in Pseudomonas Aeruginosa. PloS One 7 (8), e42973
Not in our library10.1371/journal.pone.0042973
3.
Aldrovandi M. Banthiya S. Meckelmann S. Zhou Y. Kuhn H. (2018 ). Specific Oxygenation of Plasma Membrane Phospholipids by Pseudomonas Aeruginosa Lipoxygenase Induces Structural and Functional Alterations in Mammalian Cells. Biochim. Biophys. Acta 1863 (2), 152–164
Not in our library10.1016/j.bbalip.2017.11.005
4.
Al-Hasan M. N. Wilson J. W. Lahr B. D. Eckel-Passow J. E. Baddour L. M. (2008 ). Incidence of Pseudomonas Aeruginosa Bacteremia: A Population-Based Study. Am. J. Med. 121 (8), 702–708
Not in our library10.1016/j.amjmed.2008.03.029
5.
Ali S. O. Yu X. Q. Robbie G. J. Wu Y. Shoemaker K. Yu L.. (2019 ). Phase 1 Study of MEDI3902, an Investigational Anti-Pseudomonas Aeruginosa PcrV and Psl Bispecific Human Monoclonal Antibody, in Healthy Adults. Clin. Microbiol. Infect 25 (5), 629.e621–629.e626
Not in our library10.1016/j.cmi.2018.08.004
6.
Anantharajah A. Faure E. Buyck J. M. Sundin C. Lindmark T. Mecsas J.. (2016 ). Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 Impairs Pseudomonas Aeruginosa Pathogenicity and Inflammasome Activation. J. Infect. Dis. 214 (7), 1105–1116
Not in our library10.1093/infdis/jiw295
7.
Baer M. Sawa T. Flynn P. Luehrsen K. Martinez D. Wiener-Kronish J. P (2009 ). An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity. Infection and Immunity 77(3), 1083–90. 10.1128/IAI.00815-08
Not in our library10.1128/iai.00815-08
8.
Balasubramanian D. Schneper L. Kumari H. Mathee K. (2012 ). A Dynamic and Intricate Regulatory Network Determines Pseudomonas Aeruginosa Virulence. Nucleic Acids Res. 41(1), 1–20
Not in our library10.1093/nar/gks1039
9.
Ball G. Durand É. Lazdunski A. Filloux A. (2002 ). A Novel Type II Secretion System in Pseudomonas Aeruginosa. Mol. Microbiol. 43 (2), 475–485
Not in our library10.1046/j.1365-2958.2002.02759.x
10.
Ball G. Viarre V. Garvis S. Voulhoux R. Filloux A. (2012 ). Type II-Dependent Secretion of a Pseudomonas Aeruginosa DING Protein. Res. Microbiol. 163 (6), 457–469
Not in our library10.1016/j.resmic.2012.07.007
11.
Barken K. B. Pamp S. J. Yang L. Gjermansen M. Bertrand J. J. Klausen M.. (2010 ). Roles of Type IV Pili, Flagellum-Mediated Motility and Extracellular DNA in the Formation of Mature Multicellular Structures in Pseudomonas Aeruginosa Biofilms. Environ. Microbiol. 10 (9), 2331–43
Not in our library10.1111/j.1462-2920.2008.01658.x
12.
Barraud N. Hassett D. J. Hwang S.-H. Rice S. A. Kjelleberg S. Webb J. S. (2006 ). Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas Aeruginosa. J. Bacteriol 188 (21), 7344–7353
Not in our library10.1128/jb.00779-06
13.
Basler M. Ho B. Mekalanos J. (2013 ). Tit-For-Tat: Type VI Secretion System Counterattack During Bacterial Cell-Cell Interactions. Cell 152 (4), 884–894
Not in our library10.1016/j.cell.2013.01.042
14.
Basso P. Ragno M. Elsen S. Reboud E. Golovkine G. Bouillot S.. (2017 ). Pseudomonas Aeruginosa Pore-Forming Exolysin and Type IV Pili Cooperate to Induce Host Cell Lysis. MBio 8 (1), e02250–e02216
Not in our library10.1128/mbio.02250-16
15.
Baer M. Sawa T. Flynn P. Luehrsen K. Martinez D. Wiener-Kronish J.P. (2009 ). An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity. Infection and Immunity 77(3), 1083-1090. doi:.x
Not in our library10.1128/iai.00815-08
16.
Bianchi S. M. Prince L. R. McPhillips K. Allen L. Marriott H. M. Taylor G. W.. (2008 ). Impairment of Apoptotic Cell Engulfment by Pyocyanin, a Toxic Metabolite of Pseudomonas Aeruginosa. Am. J. Respir. Crit. Care Med. 177 (1), 35–43
Not in our library10.1164/rccm.200612-1804oc
17.
Bleves S (2016 ). Game of Trans-Kingdom Effectors. Trends Microbiol. 24(10), 773–774
Not in our library10.1016/j.tim.2016.08.002
18.
Bleves S. Viarre V. Salacha R. Michel G. P. F. Filloux A. Voulhoux R. (2010 ). Protein Secretion Systems in Pseudomonas Aeruginosa: A Wealth of Pathogenic Weapons. Int. J. Med. Microbiol. 300 (8), 534–543
Not in our library10.1016/j.ijmm.2010.08.005
19.
Bondareva N. E. Soloveva A. V. Sheremet A. B. Koroleva E. A. Kapotina L. N. Morgunova E. Y.. (2022 ). Preventative Treatment With Fluorothiazinon Suppressed Acinetobacter Baumannii-Associated Septicemia in Mice. J. Antibiotics 75 (3), 155–163
Not in our library10.1038/s41429-022-00504-y
20.
Bonneau A. Roche B. Schalk I. J. (2020 ). Iron Acquisition in Pseudomonas Aeruginosa by the Siderophore Pyoverdine: An Intricate Interacting Network Including Periplasmic and Membrane Proteins. Sci. Rep. 10 (1), 1–11
Not in our library10.1038/s41598-019-56913-x
21.
Bouillot S. Pont S. Gallet B. Moriscot C. Huber P. (2020 ). Inflammasome Activation by Pseudomonas Aeruginosa 'S ExlA Pore-Forming Toxin is Detrimental for the Host. Cell. Microbiol. 22 (11), e13251
Not in our library10.1111/cmi.13251
22.
Boyd A. Chakrabarty A. M. (1995 ). Pseudomonas Aeruginosa Biofilms: Role of the Alginate Exopolysaccharide. J. Ind. Microbiol. 15 (3), 162–168
Not in our library10.1007/bf01569821
23.
Bradshaw J. L. Caballero A. R. Bierdeman M. A. Adams K. V. Pipkins H. R. Tang A.. (2018 ). Pseudomonas Aeruginosa Protease IV Exacerbates Pneumococcal Pneumonia and Systemic Disease. Msphere 3 (3), e00212–e00218
Not in our library10.1128/msphere.00212-18
24.
Burrows L. L. (2012 a). Pseudomonas Aeruginosa Twitching Motility: Type IV Pili in Action. Annu. Rev. Microbiol. 66 (1), 493–520
Not in our library10.1146/annurev-micro-092611-150055
25.
Burrows L. L. (2012 b). Pseudomonas Aeruginosa Twitching Motility: Type IV Pili in Action. Annu. Rev. Microbiol. 66, 493–520
Not in our library10.1146/annurev-micro-092611-150055
26.
Campodónico V. L. Llosa N. J. Grout M. Döring G. Maira-Litrán T. Pier G. B. (2010 ). Evaluation of Flagella and Flagellin of Pseudomonas Aeruginosa as Vaccines. Infect Immun. 78 (2), 746–755
Not in our library10.1128/iai.00806-09
27.
Carmeli Y. Troillet N. Eliopoulos G. M. Samore M. H. (1999 ). Emergence of Antibiotic-Resistant Pseudomonas Aeruginosa: Comparison of Risks Associated With Different Antipseudomonal Agents. Antimicro Agents chemother 43 (6), 1379–1382
Not in our library10.1128/aac.43.6.1379
28.
Casilag F. Lorenz A. Krueger J. Klawonn F. Weiss S. Häussler S. (2015 ). The LasB Elastase of Pseudomonas Aeruginosa Acts in Concert With Alkaline Protease AprA to Prevent Flagellin-Mediated Immune Recognition. Infect Immun. 84 (1), 162
Not in our library10.1128/iai.00939-15
29.
Cegelski L. Marshall G. R. Eldridge G. R. Hultgren S. J. (2008 ). The Biology and Future Prospects of Antivirulence Therapies. Nat. Rev. Microbiol. 6 (1), 17–27
Not in our library10.1038/nrmicro1818
30.
Cheng Z. (2016 ). A Pseudomonas Aeruginosa-Secreted Protease Modulates Host Intrinsic Immune Responses, But How? BioEssays 38 (11), 1084–1092
Not in our library10.1002/bies.201600101
31.
Chen L. Zou Y. She P. Wu Y. (2015 ). Composition, Function, and Regulation of T6SS in Pseudomonas Aeruginosa. Microb Res. 172, 19–25
Not in our library10.1016/j.micres.2015.01.004
32.
Choy M. H. Stapleton F. Willcox M. D. P. Zhu H. (2008 ). Comparison of Virulence Factors in Pseudomonas Aeruginosa Strains Isolated From Contact Lens- and non-Contact Lens-Related Keratitis. J. Med. Microbiol. 57 (12), 1539–1546
Not in our library10.1099/jmm.0.2008/003723-0
33.
Coburn B. Sekirov I. Finlay B. B. (2007 ). Type III Secretion Systems and Disease. Clin. Microbiol. Rev. 20 (4), 535–549
Not in our library10.1128/cmr.00013-07
34.
Colvin K. M. Irie Y. Tart C. S. Urbano R. Whitney J. C. Ryder C.. (2012 ). The Pel and Psl Polysaccharides Provide Pseudomonas Aeruginosa Structural Redundancy Within the Biofilm Matrix. Environ. Microbiol. 14 (8), 1913–1928
Not in our library10.1111/j.1462-2920.2011.02657.x
35.
Cornelis G. R. (2006 ). The Type III Secretion Injectisome. Nat. Rev. Microbiol. 4 (11), 811–825
Not in our library10.1038/nrmicro1526
36.
Cornelis G. R. (2010 a). The Type III Secretion Injectisome, a Complex Nanomachine for Intracellular ‘Toxin’ Delivery. Biol. Chem. 391 (7), 745–751
Not in our library10.1515/bc.2010.079
37.
Cornelis P. (2010 b). Iron Uptake and Metabolism in Pseudomonads. Appl. Microbiol. Biotechnol. 86 (6), 1637–1645
Not in our library10.1007/s00253-010-2550-2
38.
Craig L. Forest K. T. Maier B. (2019 ). Type IV Pili: Dynamics, Biophysics and Functional Consequences. Nat. Rev. Microbiol. 17 (7), 429–440
Not in our library10.1038/s41579-019-0195-4
39.
Cryz S. Fürer E. Sadoff J. Germanier R. (1987 ). “"A Polyvalent Pseudomonas Aeruginosa O-Polysaccharide-Toxin A Conjugate Vaccine,",” in Basic Research and Clinical Aspects of Pseudomonas Aeruginosa eds.Döring G. Holder I. A. Botzenhart K. (Tübingen:Karger Publishers) 39, 249–255
Not in our library10.1159/000414350
40.
Cryz S. Jr. Lang A. Rüdeberg A. Wedgwood J. Que J. Fürer E.. (1997 ). Immunization of Cystic Fibrosis Patients With a Pseudomonas Aeruginosa O-Polysaccharide-Toxin A Conjugate Vaccine. Behring Inst Mitt. 98), 345–349.
Not in our library
41.
Cunrath O. Graulier G. Lopez A. C. Perard J. Fechter P. (2020 ). The Pathogen Pseudomonas Aeruginosa Optimizes the Production of the Siderophore Pyochelin Upon Environmental Challenges. Metallomics 12, 2108–2120
Not in our library10.1039/d0mt00029a
42.
Cutruzzolà F. Frankenberg-Dinkel N. O'Toole G. A. (2016 ). Origin and Impact of Nitric Oxide in Pseudomonas Aeruginosa Biofilms. J. Bacteriol 198 (1), 55–65
Not in our library10.1128/jb.00371-15
43.
Daddaoua A. Molina-Santiago C. la Torre J. D. Krell T. Ramos J. L (2014 ). GtrSand GltR Form a Two-Component System: The Central Role of 2-Ketogluconate in the Expression of Exotoxin A and Glucose Catabolic Enzymes in Pseudomonas Aeruginosa. Nucleic Acids Res 42(12), 7654-7663. doi:.x
Not in our library10.1093/nar/gku496
44.
D'Angelo F. Baldelli V. Halliday N. Pantalone P. Polticelli F. Fiscarelli E.. (2018 ). Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the Pqs Quorum-Sensing System of Pseudomonas Aeruginosa. Antimicrob. Agents Chemother. 62 (11), e01296–01318
Not in our library10.1128/aac.01296-18
45.
Dao N. Joshi-Datar A. Lepine F. Bauerle E. Olakanmi O. Beer K.. (2011 ). Active Starvation Responses Mediate Antibiotic Tolerance in Biofilms and Nutrient-Limited Bacteria. Science 334 (6058), 982–986
Not in our library10.1126/science.1211037
46.
Dar H. H. Epperly M. W. Tyurin V. A. Amoscato A. A. Anthonymuthu T. S. Souryavong A. B.. (2022 ). P. Aeruginosa Augments Irradiation Injury via 15-Lipoxygenase Catalyzed Generation of 15-HpETE-PE and Induction of Theft-Ferroptosis. JCI Insight 7 (4), e156013
Not in our library10.1172/jci.insight.156013
47.
Dasgupta N. Arora S. K. Ramphal R. (2004 ). “"The Flagellar System of Pseudomonas Aeruginosa,",” in Pseudomonas: Volume 1 Genomics, Life Style and Molecular Architecture. Ed. Ramos J.-L. (Boston, MA: Springer US), 675–698
Not in our library10.1007/978-1-4419-9086-0_22
48.
Dickey S. W. Cheung G. Y. C. Otto M. (2017 ). Different Drugs for Bad Bugs: Antivirulence Strategies in the Age of Antibiotic Resistance. Nat. Rev. Drug Discovery 16 (7), 457–471
Not in our library10.1038/nrd.2017.23
49.
Microbe Profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat · 2020
No notice
50.
DiGiandomenico A. Keller A. E. Gao C. Rainey G. J. Warrener P. Camara M. M.. (2014 ). A Multifunctional Bispecific Antibody Protects Against Pseudomonas Aeruginosa. Sci. Trans. Med. 6 (262), 262ra155–262ra155
Not in our library10.1126/scitranslmed.3009655
51.
Döring G. (2010 ). Prevention of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients. Int. J. Med. Microbiol. 300 (8), 573–577
Not in our library10.1016/j.ijmm.2010.08.010
52.
Duong F. Bonnet E. Géli V. Lazdunski A. Filloux A. (2001 ). The AprX Protein of Pseudomonas Aeruginosa: A New Substrate for the Apr Type I Secretion System. Gene 262 (1-2), 147–153
Not in our library10.1016/s0378-1119(00)00541-2
53.
Ellis T. N. Kuehn M. J. (2010 ). Virulence and Immunomodulatory Roles of Bacterial Outer Membrane Vesicles. Microbiol. Mol. Biol. Rev. 74 (1), 81–94
Not in our library10.1128/mmbr.00031-09
54.
Elsen S. Huber P. Bouillot S. Couté Y. Fournier P. Dubois Y.. (2014 ). A Type III Secretion Negative Clinical Strain of Pseudomonas Aeruginosa Employs a Two-Partner Secreted Exolysin to Induce Hemorrhagic Pneumonia. Cell Host Microbe 15 (2), 164–176
Not in our library10.1016/j.chom.2014.01.003
55.
Engel L. S. Hill J. M. Caballero A. R. Green L. C. O'Callaghan R. J. (1998 ). Protease IV, a Unique Extracellular Protease and Virulence Factor From Pseudomonas Aeruginosa. J. Biol. Chem. 273 (27), 16792–16797
Not in our library10.1074/jbc.273.27.16792
56.
Faezi S. Bahrmand A. R. Mahdavi M. Siadat S. D. Sardari S. Nikokar I.. (2017 ). Preparation of Pseudomonas Aeruginosa Alginate-Flagellin Immunoconjugate. Biologicals 47, 11–17
Not in our library10.1016/j.biologicals.2017.04.001
57.
Feng C. Huang Y. He W. Cheng X. Liu H. Huang Y.. (2019 ). Tanshinones: First-In-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of Pseudomonas Aeruginosa for Antibiotic Therapy. ACS Cent. Sci. 5 (7), 1278–1288
Not in our library10.1021/acscentsci.9b00452
58.
Feuillet V. Medjane S. Mondor I. Demaria O. Pagni P. P. Galán J. E.. (2006 ). Involvement of Toll-Like Receptor 5 in the Recognition of Flagellated Bacteria. Proc. Natl. Acad. Sci. United States America 103 (33), 12487–12492
Not in our library10.1073/pnas.0605200103
59.
Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition · 2019
No notice
60.
Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition · 2019
No notice
61.
Franklin M. Nivens D. Weadge J. Howell P. (2011 ). Biosynthesis of the Pseudomonas Aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl. Front. Microbiol. 2
Not in our library10.3389/fmicb.2011.00167
62.
Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa · 2021
Not checked
63.
Galdino A. C. M. Viganor L. de Castro A. A. da Cunha E. F. F. Mello T. P. Mattos L. M.. (2019 ). Disarming Pseudomonas Aeruginosa Virulence by the Inhibitory Action of 1,10-Phenanthroline-5,6-Dione-Based Compounds: Elastase B (LasB) as a Chemotherapeutic Target. Front. Microbiol. 10, 1701
Not in our library10.3389/fmicb.2019.01701
64.
The Type VI Secretion System: A Dynamic System for Bacterial Communication? · 2017
No notice
65.
Gellatly S. L. Hancock R. E. W. (2013 ). Pseudomonas Aeruginosa: New Insights Into Pathogenesis and Host Defenses. Pathog. Dis. 67 (3), 159–173
Not in our library10.1111/2049-632x.12033
66.
Goldberg J. B. Pier G. B. (1996 ). Pseudomonas Aeruginosa Lipopolysaccharides and Pathogenesis. Trends Microbiol. 4 (12), 490–494
Not in our library10.1016/s0966-842x(97)82911-3
67.
Gómez M. I. Prince A. (2007 ). Opportunistic Infections in Lung Disease: Pseudomonas Infections in Cystic Fibrosis. Curr. Opin. Pharmacol. 7 (3), 244–251
Not in our library10.1016/j.coph.2006.12.005
68.
Hahn H. P. (1997 ). The Type-4 Pilus is the Major Virulence-Associated Adhesin of Pseudomonas Aeruginosa – a Review. Gene 192 (1), 99–108
Not in our library10.1016/s0378-1119(97)00116-9
69.
Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa · 2016
No notice
70.
Hanessian S. Regan W. Watson D. Haskell T. H. (1971 ). Isolation and Characterization of Antigenic Components of a New Heptavalent Pseudomonas Vaccine. Nat. New Biol. 229 (7), 209–210
Not in our library10.1038/newbio229209a0
71.
Hassan R. El-Naggar W. Abd El-Aziz A. M. Shaaban M. Kenawy H. I. Ali Y. M. (2018 ). Immunization With Outer Membrane Proteins (OprF and OprI) and Flagellin B Protects Mice From Pulmonary Infection With Mucoid and Nonmucoid Pseudomonas Aeruginosa. J. microbiol Immunol. infect 51 (3), 312–320
Not in our library10.1016/j.jmii.2016.08.014
72.
Hatano K. Pier G. B. (1998 ). Complex Serology and Immune Response of Mice to Variant High-Molecular-Weight O Polysaccharides Isolated From Pseudomonas Aeruginosa Serogroup O2 Strains. Infect Immun. 66 (8), 3719–3726
Not in our library10.1128/iai.66.8.3719-3726.1998
73.
Hauser A. R. (2009 ). The Type III Secretion System of Pseudomonas Aeruginosa: Infection by Injection. Nat. Rev. Microbiol. 7 (9), 654–665
Not in our library10.1038/nrmicro2199
74.
Hemmati F. Salehi R. Ghotaslou R. Kafil H. S. Hasani A. Gholizadeh P.. (2020 ). Quorum Quenching: A Potential Target for Antipseudomonal Therapy. Infect Drug Resistance 13, 2989
Not in our library10.2147/idr.s263196
75.
Henderson I. R. Navarrogarcia F. Desvaux M. Fernandez R. C. Ala'Aldeen D. (2004 ). Type V Protein Secretion Pathway: The Autotransporter Story. Microbiol. Mol. Biol. Rev. MMBR 68 (4), 692–744
Not in our library10.1128/mmbr.68.4.692-744.2004
76.
Hengzhuang W. Song Z. Ciofu O. Onsøyen E. Rye P. D. Høiby N. (2016 ). OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model. Antimicrobial Agents and Chem. 60 (5), 2620–26
Not in our library10.1128/aac.01721-15
77.
Hentzer M. Wu H. Andersen J. B. Riedel K. Rasmussen T. B. Bagge N.. (2003 ). Attenuation of Pseudomonas Aeruginosa Virulence by Quorum Sensing Inhibitors. EMBO J. 22 (15), 3803–3815
Not in our library10.1093/emboj/cdg366
78.
Hirayama T. Kato I. Matsuda F. Noda M. (2013 ). Crystallization and Some Properties of Leukocidin From Pseudomonas Aeruginosa. Microbiol. Immunol. 27 (7), 575–588
Not in our library10.1111/j.1348-0421.1983.tb00619.x
79.
Hogardt M. Heesemann J. (2013 ). “"Microevolution of Pseudomonas Aeruginosa to a Chronic Pathogen of the Cystic Fibrosis Lung,",” in Between Pathogenicity and Commensalism. Eds. Dobrindt U. Hacker J. H. Svanborg C. (Berlin, Heidelberg: Springer Berlin Heidelberg), 91–118
Not in our library10.1007/82_2011_199
80.
Holder I. Wheeler R. Montie T. (1982 ). Flagellar Preparations From Pseudomonas Aeruginosa: Animal Protection Studies. Infect Immun. 35 (1), 276–280
Not in our library10.1128/iai.35.1.276-280.1982
81.
Homma J. Y. Matsuura M. Shibata M. Kazuyama Y. Kato I. (1984 ). Production of Leukocidin by Clinical Isolates of Pseudomonas Aeruginosa and Antileukocidin Antibody From Sera of Patients With Diffuse Panbronchiolitis. J. Clin. Microbiol. 20 (5), 855–859
Not in our library10.1128/jcm.20.5.855-859.1984
82.
Hood R. D. Singh P. Hsu F. Güvener T. Carl M. A. Trinidad R. R.. (2010 ). A Type VI Secretion System of Pseudomonas Aeruginosa Targets a Toxin to Bacteria. Cell Host Microbe 7 (1), 25–37
Not in our library10.1016/j.chom.2009.12.007
83.
Horna G. Amaro C. Palacios A. Guerra H. Ruiz J. (2019 ). High Frequency of the Exou+/Exos+ Genotype Associated With Multidrug-Resistant “High-Risk Clones” of Pseudomonas Aeruginosa Clinical Isolates From Peruvian Hospitals. Sci. Rep. 9 (1), 10874
Not in our library10.1038/s41598-019-47303-4
84.
Horna G. Ruiz J. (2021 a). Type 3 Secretion System as an Anti-Pseudomonal Target. Microbial Pathogen 155, 104907
Not in our library10.1016/j.micpath.2021.104907
85.
Horna G. Ruiz J. (2021 b). Type 3 Secretion System of Pseudomonas Aeruginosa. Microb Res. 246, 126719
Not in our library10.1016/j.micres.2021.126719
86.
Horn M. P. Zuercher A. W. Imboden M. A. Rudolf M. P. Lazar H. Wu H.. (2010 ). Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas Aeruginosa Serotype IATS-O11. Antimicro Agents Chemother 54 (6), 2338–2344
Not in our library10.1128/aac.01142-09
87.
The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology · 2019
No notice
88.
Hwang H.-J. Choi H. Hong S. Moon H. R. Lee J.-H. (2021 ). Antipathogenic Compounds That Are Effective at Very Low Concentrations and Have Both Antibiofilm and Antivirulence Effects Against Pseudomonas Aeruginosa. Microbiol. Spectr. 9 (2), e0024921–e0024921
Not in our library10.1128/spectrum.00249-21
89.
Jacob-Dubuisson F. Locht C. Antoine R. (2001 ). Two-Partner Secretion in Gram-Negative Bacteria: A Thrifty, Specific Pathway for Large Virulence Proteins. Mol. Microbiol. 40 (2), 306–13
Not in our library10.1046/j.1365-2958.2001.02278.x
90.
Jain R. Beckett V. V. Konstan M. W. Accurso F. J. Burns J. L. Mayer-Hamblett N.. (2018 ). KB001-A, a Novel Anti-Inflammatory, Found to be Safe and Well-Tolerated in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa. J. Cystic Fibrosis 17 (4), 484–491
Not in our library10.1016/j.jcf.2017.12.006
91.
Jiang F. Waterfield N. Yang J. Yang G. Jin Q. (2014 ). A Pseudomonas Aeruginosa Type VI Secretion Phospholipase D Effector Targets Both Prokaryotic and Eukaryotic Cells. Cell Host Microbe 15 (5), 600–610
Not in our library10.1016/j.chom.2014.04.010
92.
Jyot J. Balloy V. Jouvion G. Verma A. Touqui L. Huerre M.. (2011 ). Type II Secretion System of Pseudomonas Aeruginosa: In Vivo Evidence of a Significant Role in Death Due to Lung Infection. J. Infect. Dis. 203 (10), 1369–1377
Not in our library10.1093/infdis/jir045
93.
Kalms J. Banthiya S. Yoga E. G. Hamberg M. Holzhutter H. G. Kuhn H.. (2017 ). The Crystal Structure of Pseudomonas Aeruginosa Lipoxygenase Ala420Gly Mutant Explains the Improved Oxygen Affinity and the Altered Reaction Specificity. BBA - Mol. Cell Biol. Lipids 1862 (5), 463–473
Not in our library10.1016/j.bbalip.2017.01.003
94.
Kany A. M. Sikandar A. Haupenthal J. Yahiaoui S. Maurer C. K. Proschak E.. (2018 ). Binding Mode Characterization and Early in Vivo Evaluation of Fragment-Like Thiols as Inhibitors of the Virulence Factor LasB From Pseudomonas Aeruginosa. ACS Infect. Dis. 4 (6), 988–997
Not in our library10.1021/acsinfecdis.8b00010
95.
Kaya C. Walter I. Yahiaoui S. Sikandar A. Alhayek A. Konstantinović J.. (2022 ). Substrate-Inspired Fragment Merging and Growing Affords Efficacious LasB Inhibitors. Angew Chem. Int. Ed Engl. 61 (5), e202112295
Not in our library10.1002/anie.202112295
96.
Kessler E. Safrin M. Abrams W. R. Rosenbloom J. Ohman D. E. (1997 ). Inhibitors and Specificity of Pseudomonas Aeruginosa LasA. J. Biol. Chem. 272 (15), 9884–9889
Not in our library10.1074/jbc.272.15.9884
97.
Kessler E. Safrin M. Gustin J. K. Ohman D. E. (1998 ). Elastase and the LasA Protease of Pseudomonas Aeruginosa are Secreted With Their Propeptides. J. Biol. Chem. 273 (46), 30225–30231
Not in our library10.1074/jbc.273.46.30225
98.
Kim S.-K. Ngo H. X. Dennis E. K. Thamban Chandrika N. DeShong P. Garneau-Tsodikova S.. (2021 ). Inhibition of Pseudomonas Aeruginosa Alginate Synthesis by Ebselen Oxide and Its Analogues. ACS Infect. Dis. 7 (6), 1713–1726
Not in our library10.1021/acsinfecdis.1c00045
99.
Kirienko D. R. Kang D. Kirienko N. V. (2018 ). Novel Pyoverdine Inhibitors Mitigate Pseudomonas Aeruginosa Pathogenesis. Front. Microbiol. 9
Not in our library10.3389/fmicb.2018.03317
100.
Kollberg H. Carlander D. Olesen H. Wejåker P.-E. Johannesson M. Larsson A. (2003 ). Oral Administration of Specific Yolk Antibodies (IgY) may Prevent Pseudomonas Aeruginosa Infections in Patients With Cystic Fibrosis: A Phase I Feasibility Study. Pediatr. Pulmonol 35 (6), 433–440
Not in our library10.1002/ppul.10290
101.
König B. Vasil M. L. König W. (1997 ). Role of Haemolytic and Non-Haemolytic Phospholipase C From Pseudomonas Aeruginosa in Interleukin-8 Release From Human Monocytes. J. Med. Microbiol. 46 (6), 471–478
Not in our library10.1099/00222615-46-6-471
102.
Lamont I. L. Beare P. A. Ochsner U. (2002 ). Siderophore-Mediated Signaling Regulates Virulence Factor Production in Pseudomonas Aeruginosa. Proc. Natl. Acad. Sci. United States America 99 (10), 7072–7077
Not in our library10.1073/pnas.092016999
103.
Lau G. W. Hassett D. J. Ran H. Kong F. (2004 ). The Role of Pyocyanin in Pseudomonas Aeruginosa Infection. Trends Mol. Med. 10 (12), 599–606
Not in our library10.1016/j.molmed.2004.10.002
104.
Lazar H. Horn M. P. Zuercher A. W. Imboden M. A. Durrer P. Seiberling M.. (2009 ). Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas Aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers. Antimicro Agents Chemother 53 (8), 3442–3446
Not in our library10.1128/aac.01699-08
105.
Lewis K. (2001 ). Riddle of Biofilm Resistance. Antimicro Agents chemother 45 (4), 999–1007
Not in our library10.1128/aac.45.4.999-1007.2001
106.
Li S. Chen S. Fan J. Cao Z. Ouyang W. Tong N.. (2018 ). Anti-Biofilm Effect of Novel Thiazole Acid Analogs Against Pseudomonas Aeruginosa Through IQS Pathways. Eur. J. Medic Chem. 145, 64–73
Not in our library10.1016/j.ejmech.2017.12.076
107.
Loos A. Weich N. Woo J. Lalonde G. Yee L. Dummer W.. (2019 ). “"674. Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas Aeruginosa Human Monoclonal Antibody AR-105",” in Open Forum Infectious Diseases
Not in our library10.1093/ofid/ofz360.742
108.
Lu J. Zhang C. Hui Y. L. Show P. L. Lu Z. (2020 ). Overproduction of Lipoxygenase From Pseudomonas Aeruginosa in Escherichia Coli by Auto-Induction Expression and its Application in Triphenylmethane Dyes Degradation. J. Biosci Bioeng 129 (3), 327–332
Not in our library10.1016/j.jbiosc.2019.09.006
109.
Maeda T. García-Contreras R. Pu M. Sheng L. Garcia L. R. Tomás M.. (2012 ). Quorum Quenching Quandary: Resistance to Antivirulence Compounds. ISME J. 6 (3), 493–501
Not in our library10.1038/ismej.2011.122
110.
Malloy J. L. Veldhuizen R. A. Thibodeaux B. A. O'Callaghan R. J. Wright J. R. (2005 ). Pseudomonas Aeruginosa Protease IV Degrades Surfactant Proteins and Inhibits Surfactant Host Defense and Biophysical Functions. Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2), L409
Not in our library10.1152/ajplung.00322.2004
111.
Ma L. Lu H. Sprinkle A. Parsek M. R. Wozniak D. J. (2007 ). Pseudomonas Aeruginosa Psl is a Galactose- and Mannose-Rich Exopolysaccharide. J. bacteriol 189 (22), 8353–8356
Not in our library10.1128/jb.00620-07
112.
Mann E. E. Wozniak D. J. (2012 ). Pseudomonas Biofilm Matrix Composition and Niche Biology. FEMS Microbiol. Rev. 36 (4), 893–916
Not in our library10.1111/j.1574-6976.2011.00322.x
113.
Mariencheck W. I. Alcorn J. F. Palmer S. M. Wright J. R. (2003 ). Pseudomonas Aeruginosa Elastase Degrades Surfactant Proteins A and D. Am. J. Respir. Cell Mol. Biol. 28 (4), 528–537
Not in our library10.1165/rcmb.2002-0141oc
114.
Matsumoto T. Tateda K. Furuya N. Miyazaki S. Ohno A. Ishii Y.. (1998 ). Efficacies of Alkaline Protease, Elastase and Exotoxin A Toxoid Vaccines Against Gut-Derived Pseudomonas Aeruginosa Sepsis in Mice. J. Med. Microbiol. 47 (4), 303–308
Not in our library10.1099/00222615-47-4-303
115.
Maura D. Ballok A. E. Rahme L. G. (2016 ). Considerations and Caveats in Anti-Virulence Drug Development. Curr. Opin. Microbiol. 33, 41–46
Not in our library10.1016/j.mib.2016.06.001
116.
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections · 2019
Corrected
117.
May T. B. Shinabarger D. Maharaj R. Kato J. Chu L. DeVault J. D.. (1991 ). Alginate Synthesis by Pseudomonas Aeruginosa: A Key Pathogenic Factor in Chronic Pulmonary Infections of Cystic Fibrosis Patients. Clin. Microbiol. Rev. 4 (2), 191–206
Not in our library10.1128/cmr.4.2.191
118.
Pseudomonas Exotoxin A: optimized by evolution for effective killing · 2015
No notice
119.
Miller S. I. Ernst R. K. Bader M. W. (2005 ). LPS, TLR4 and Infectious Disease Diversity. Nat. Rev. Microbiol. 3 (1), 36–46
Not in our library10.1038/nrmicro1068
120.
Monturiol-Gross L. Villalta-Romero F. Flores-Díaz M. Alape-Girón A. (2021 ). Bacterial Phospholipases C With Dual Activity: Phosphatidylcholinesterase and Sphingomyelinase. FEBS Open Bio 11 (12), 3262–3275
Not in our library10.1002/2211-5463.13320
121.
Morello E. Pérez-Berezo T. Boisseau C. Baranek T. Guillon A. Bréa D.. (2019 a). Pseudomonas Aeruginosa Lipoxygenase LoxA Contributes to Lung Infection by Altering the Host Immune Lipid Signaling. Front. Microbiol. 10
Not in our library10.3389/fmicb.2019.01826
122.
Morello E. Pérez-Berezo T. Boisseau C. Baranek T. Si-Tahar M. (2019 b). Pseudomonas Aeruginosa Lipoxygenase LoxA Contributes to Lung Infection by Altering the Host Immune Lipid Signaling. Front. Microbiol. 10
Not in our library10.3389/fmicb.2019.01826
123.
Mougous J. D. Cuff M.E. Raunser S. Shen A. Zhou M. Gifford C.A. (2006 ). A Virulence Locus of Pseudomonas Aeruginosa Encodes a Protein Secretion Apparatus. Science (New York, N.Y.) 312 (5779), 1526–1530
Not in our library10.1126/science.1128393
124.
Mühlen S. Dersch P. (2016 ). “"Anti-Virulence Strategies to Target Bacterial Infections,",” in How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives. Eds. Stadler M. Dersch P. (Cham: Springer International Publishing), 147–183
Not in our library10.1007/82_2015_490
125.
A Dual-Specificity Inhibitor Targets Polyphosphate Kinase 1 and 2 Enzymes To Attenuate Virulence of Pseudomonas aeruginosa · 2021
Not checked
126.
Newman J. W. Floyd R. V. Fothergill J. L. (2017 ). The Contribution of Pseudomonas Aeruginosa Virulence Factors and Host Factors in the Establishment of Urinary Tract Infections. FEMS Microbiol. Lett. 364 (15), 1–11
Not in our library10.1093/femsle/fnx124
127.
Nilsson E. Amini A. Wretlind B. Larsson A. (2007 ). Pseudomonas Aeruginosa Infections are Prevented in Cystic Fibrosis Patients by Avian Antibodies Binding Pseudomonas Aeruginosa Flagellin. J. Chromatogr. B 856 (1), 75–80
Not in our library10.1016/j.jchromb.2007.05.029
128.
Nivens D. E. Ohman D. E. Williams J. Franklin M. J. (2001 ). Role of Alginate and its O Acetylation in Formation of Pseudomonas Aeruginosa Microcolonies and Biofilms. J. bacteriol 183 (3), 1047–1057
Not in our library10.1128/jb.183.3.1047-1057.2001
129.
Notti R. Q. Stebbins C. E. (2016 ). The Structure and Function of Type III Secretion Systems. Microbiol. Spectr. 4 (1), 4.1. 09
Not in our library10.1128/microbiolspec.vmbf-0004-2015
130.
O'Callaghan R. Caballero A. Tang A. Bierdeman M. (2019 ). Pseudomonas Aeruginosa Keratitis: Protease IV and PASP as Corneal Virulence Mediators. Microorganisms 7 (9), 281
Not in our library10.3390/microorganisms7090281
131.
O'Donnell J. N. Bidell M. R. Lodise T. P. (2020 ). Approach to the Treatment of Patients With Serious Multidrug-Resistant Pseudomonas Aeruginosa Infections. Pharmacother: J. Hum. Pharmacol. Drug Ther. 40 (9), 952–969
Not in our library10.1002/phar.2449
132.
O’Loughlin C. T. Miller L. C. Siryaporn A. Drescher K. Semmelhack M. F. Bassler B. L. (2013 ). A Quorum-Sensing Inhibitor Blocks Pseudomonas Aeruginosa Virulence and Biofilm Formation. Proc. Natl. Acad. Sci. 110 (44), 17981–17986
Not in our library10.1073/pnas.1316981110
133.
Overhage J. Bains M. Brazas M. Hancock R. (2008 ). Swarming of Pseudomonas Aeruginosa Is a Complex Adaptation Leading to Increased Production of Virulence Factors and Antibiotic Resistance. J. Bacteriol 190 (8), 2671–2679
Not in our library10.1128/jb.01659-07
134.
Ozer E. Yaniv K. Chetrit E. Boyarski A. Meijler M. M. Berkovich R.. (2021 ). An Inside Look at a Biofilm: Pseudomonas Aeruginosa Flagella Biotracking. Sci. Adv. 7 (24), eabg8581
Not in our library10.1126/sciadv.abg8581
135.
Pan S. Y. Shih Y. L. Huang H. H. Li L. H. Yang T. C. (2021 ). The Involvement of PacIRA System of Stenotrophomonas Maltophilia in the Uptake of Pseudomonas Aeruginosa Pyochelin and Intraspecies Competition for Iron Acquisition. J. microbiol immunol infect 55 (2), 273–281
Not in our library10.1016/j.jmii.2021.03.001
136.
Basso P Ragno M. Elsen S. Reboud E. Golovkine G. Bouillot S. (2017 ). Pseudomonas Aeruginosa Pore-Forming Exolysin and Type IV Pili Cooperate To Induce Host Cell Lysis. MBio 8 (1), e02250–e02216
Not in our library10.1128/mbio.02250-16
137.
Pérez-Pérez M. Jorge P. Pérez Rodríguez G. Pereira M. O. Lourenço A. (2017 ). Quorum Sensing Inhibition in Pseudomonas Aeruginosa Biofilms: New Insights Through Network Mining. Biofouling 33 (2), 128–142
Not in our library10.1080/08927014.2016.1272104
138.
Persat A. Inclan Y. F. Engel J. N. Stone H. A. Gitai Z. (2015 ). Type IV Pili Mechanochemically Regulate Virulence Factors in Pseudomonas Aeruginosa. Proc. Natl. Acad. Sci. 112 (24), 7563–7568
Not in our library10.1073/pnas.1502025112
139.
Pier G. B. (2007 ). Pseudomonas Aeruginosa Lipopolysaccharide: A Major Virulence Factor, Initiator of Inflammation and Target for Effective Immunity. Int. J. Med. Microbiol. 297 (5), 277–295
Not in our library10.1016/j.ijmm.2007.03.012
140.
Pseudomonas aeruginosa: resistance to the max · 2011
Not checked
141.
Poole K. McKay G. A. (2003 ). Iron Acquisition and its Control in Pseudomonas Aeruginosa: Many Roads Lead to Rome. Front. Biosci. 8 (1), 661–686
Not in our library10.2741/1051
142.
Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides · 2018
No notice
143.
Proctor L. L. Ward W. L. Roggy C. S. Koontz A. G. Clark K. M. Quinn A. P.. (2021 ). Potential Therapeutic Targets for Combination Antibody Therapy Against Pseudomonas Aeruginosa Infections. Antibiotics 10 (12), 1530
Not in our library10.3390/antibiotics10121530
144.
Quinaud M. Chabert J. Faudry E. Neumann E. Lemaire D. Pastor A.. (2005 ). The PscE-PscF-PscG Complex Controls Type III Secretion Needle Biogenesis in Pseudomonas Aeruginosa. J. Biol. Chem. 280 (43), 36293–36300
Not in our library10.1074/jbc.m508089200
145.
Polyphosphate kinase is essential for biofilm development, quorum sensing, and virulence of Pseudomonas aeruginosa · 2000
Not checked
146.
Rasko D. A. Sperandio V. (2010 ). Anti-Virulence Strategies to Combat Bacteria-Mediated Disease. Nat. Rev. Drug Discovery 9 (2), 117–128
Not in our library10.1038/nrd3013
147.
Ravel J. Cornelis P. (2003 ). Genomics of Pyoverdine-Mediated Iron Uptake in Pseudomonads. Trends Microbiol. 11 (5), 195–200
Not in our library10.1016/s0966-842x(03)00076-3
148.
Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. · 2020
Not checked
149.
Rice L. B. (2008 ). Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE. J. Infect. Dis. 197 (8), 1079–1081
Not in our library10.1086/533452
150.
Roche B. Mislin G. L. Schalk I. J. (2021 ). Identification of the Fatty Acid Coenzyme-A Ligase FadD1 as an Interacting Partner of FptX in the Pseudomonas Aeruginosa Pyochelin Pathway. FEBS Lett. 595 (3), 370–378
Not in our library10.1002/1873-3468.14012
151.
Rollet C. Gal L. Guzzo J. (2009 ). Biofilm-Detached Cells, a Transition From a Sessile to a Planktonic Phenotype: A Comparative Study of Adhesion and Physiological Characteristics in Pseudomonas Aeruginosa. FEMS Microbiol. Lett. 290 (2), 135–142
Not in our library10.1111/j.1574-6968.2008.01415.x
152.
Römling U. Balsalobre C. (2012 ). Biofilm Infections, Their Resilience to Therapy and Innovative Treatment Strategies. J. Internal Med. 272 (6), 541–561
Not in our library10.1111/joim.12004
153.
Rosenau F. Isenhardt S. Gdynia A. Tielker D. Schmidt E. Tielen P.. (2010 ). Lipase LipC Affects Motility, Biofilm Formation and Rhamnolipid Production in Pseudomonas Aeruginosa. FEMS Microbiol. Lett. 309 (1), 25–34
Not in our library10.1111/j.1574-6968.2010.02017.x
154.
Roy-Burman A. Savel R. H. Racine S. Swanson B. L. Revadigar N. S. Fujimoto J.. (2001 ). Type III Protein Secretion Is Associated With Death in Lower Respiratory and Systemic Pseudomonas Aeruginosa Infections. J. Infect. Dis. 183 (12), 1767–1774
Not in our library10.1086/320737
155.
Russell A. B Hood R. D. Bui N. K LeRoux M. Vollmer W. Mougous J. D. (2011 ). Type VI Secretion Delivers Bacteriolytic Effectors to Target Cells. Nature 475(7356), 343–7
Not in our library10.1038/nature10244
156.
Rutherford S. T. Bassler B. L. (2012 ). Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for its Control. Cold Spring Harbor Perspect. Med. 2 (11), a012427
Not in our library10.1101/cshperspect.a012427
157.
Salacha R. Kovačić F. Brochier-Armanet C. Wilhelm S. Tommassen J. Filloux A.. (2010 ). The Pseudomonas Aeruginosa Patatin-Like Protein PlpD is the Archetype of a Novel Type V Secretion System. Environ. Microbiol. 12 (6), 1498–1512
Not in our library10.1111/j.1462-2920.2010.02174.x
158.
Sampedro I. Parales R. E. Krell T. Hill J. E. (2015 ). Pseudomonas Chemotaxis. FEMS Microbiol. Rev. 39 (1), 17–46
Not in our library10.1111/1574-6976.12081
159.
Sass G. Conrad L. Nguyen T. Stevens D. A. (2020 ). The Pseudomonas Aeruginosa Product Pyochelin Interferes With Trypanosoma Cruzi Infection and Multiplication In Vitro. Trans. R. Soc. Trop. Med. Hygiene 114 (7), 492–498
Not in our library10.1093/trstmh/trz136
160.
Sato H. Frank D. (2011 ). Multi-Functional Characteristics of the Pseudomonas Aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in Other Gram-Negative Bacteria. Front. Microbiol. 2
Not in our library10.3389/fmicb.2011.00142
161.
Sato H. Frank D. W. Hillard C. J. Feix J. B. Pankhaniya R. R. Moriyama K.. (2003 ). The Mechanism of Action of the Pseudomonas Aeruginosa-Encoded Type III Cytotoxin, ExoU. EMBO J. 22 (12), 2959–2969
Not in our library10.1093/emboj/cdg290
162.
Sawa T. Yahr T. L. Ohara M. Kurahashi K. Gropper M. A. Wiener-Kronish J. P.. (1999 ). Active and Passive Immunization With the Pseudomonas V Antigen Protects Against Type III Intoxication and Lung Injury. Nat. Med. 5 (4), 392–398
Not in our library10.1038/7391
163.
Scharmann W. (1976 ). Cytotoxic Effects of Leukocidin From Pseudomonas Aeruginosa on Polymorphonuclear Leukocytes From Cattle. Infect Immun. 13 (3), 836–843
Not in our library10.1128/iai.13.3.836-843.1976
164.
Secher T. Fauconnier L. Szade A. Rutschi O. Fas S. C. Ryffel B.. (2011 ). Anti-Pseudomonas Aeruginosa Serotype O11 LPS Immunoglobulin M Monoclonal Antibody Panobacumab (KBPA101) Confers Protection in a Murine Model of Acute Lung Infection. J. Antimicro Chemother 66 (5), 1100–1109
Not in our library10.1093/jac/dkr038
165.
Shen E. P. Hsieh Y.-T. Chu H.-S. Chang S.-C. Hu F.-R. (2015 ). Correlation of Pseudomonas Aeruginosa Genotype With Antibiotic Susceptibility and Clinical Features of Induced Central Keratitis. Invest. Ophthalmol. Visual Sci. 56 (1), 365–371
Not in our library10.1167/iovs.14-15241
166.
Sheremet A. B. Zigangirova N. A. Zayakin E. S. Luyksaar S. I. Kapotina L. N. Nesterenko L. N.. (2018 ). Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-Disubstituted-4h-[1,3,4]-Thiadiazine-5-Ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas Aeruginosa Infection in Mice. BioMed. Res. Int. 2018, 5810767
Not in our library10.1155/2018/5810767
167.
Song Z. Wu H. Ciofu O. Kong K.-F. Høiby N. Rygaard J.. (2003 ). Pseudomonas Aeruginosa Alginate is Refractory to Th1 Immune Response and Impedes Host Immune Clearance in a Mouse Model of Acute Lung Infection. J. Med. Microbiol. 52 (9), 731–740
Not in our library10.1099/jmm.0.05122-0
168.
Identification of Anti-virulence Compounds That Disrupt Quorum-Sensing Regulated Acute and Persistent Pathogenicity · 2014
No notice
169.
Sundin C. Henriksson M. L. Hallberg B. Forsberg Å. Frithz-Lindsten E. (2001 ). Exoenzyme T of Pseudomonas Aeruginosa Elicits Cytotoxicity Without Interfering With Ras Signal Transduction. Cell. Microbiol. 3 (4), 237–246
Not in our library10.1046/j.1462-5822.2001.00108.x
170.
Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo. · 2014
Not checked
171.
Talà L. Fineberg A. Kukura P. Persat A. (2019 ). Pseudomonas Aeruginosa Orchestrates Twitching Motility by Sequential Control of Type IV Pili Movements. Nat. Microbiol. 4 (5), 774–780
Not in our library10.1038/s41564-019-0378-9
172.
Taylor P. K. Yeung A. T. Y. Hancock R. E. W. (2014 ). Antibiotic Resistance in Pseudomonas Aeruginosa Biofilms: Towards the Development of Novel Anti-Biofilm Therapies. J. Biotechnol. 191, 121–130
Not in our library10.1016/j.jbiotec.2014.09.003
173.
Terada L. S. Johansen K. A. Nowbar S. Vasil A. I. Vasil M. L. (1999 ). Pseudomonas Aeruginosa Hemolytic Phospholipase C Suppresses Neutrophil Respiratory Burst Activity. Infect Immun. 67 (5), 2371–2376
Not in our library10.1128/iai.67.5.2371-2376.1999
174.
Pseudomonas aeruginosa Biofilms · 2020
No notice
175.
Tielen P. Kuhn H. Rosenau F. Jaeger K.-E. Flemming H.-C. Wingender J. (2013 ). Interaction Between Extracellular Lipase LipA and the Polysaccharide Alginate of Pseudomonas Aeruginosa. BMC Microbiol. 13 (1), 1–12
Not in our library10.1186/1471-2180-13-159
176.
Tielen P. Rosenau F. Wilhelm S. Jaeger K.-E. Flemming H.-C. Wingender J. (2010 ). Extracellular Enzymes Affect Biofilm Formation of Mucoid Pseudomonas Aeruginosa. Microbiology 156 (7), 2239–2252
Not in our library10.1099/mic.0.037036-0
177.
Triantafilou M. Triantafilou K. (2002 ). Lipopolysaccharide Recognition: CD14, TLRs and the LPS-Activation Cluster. Trends Immunol. 23 (6), 301–304
Not in our library10.1016/s1471-4906(02)02233-0
178.
Vasil M. L. Graham L. M. Ostroff R. M. Shortridge V. D. Vasil A. I. (1991 ). Phospholipase C: Molecular Biology and Contribution to the Pathogenesis of Pseudomonas Aeruginosa. Antibiot Chemother. 44, 34–47
Not in our library10.1159/000420295
179.
Veesenmeyer J. L. Hauser A. R. Lisboa T. Rello J. (2009 ). Pseudomonas Aeruginosa Virulence and Therapy: Evolving Translational Strategies. Crit. Care Med. 37 (5), 1777–1786
Not in our library10.1097/ccm.0b013e31819ff137
180.
Verma N. Dollinger P. Kovacic F. Jaeger K.-E. Gohlke H. (2020 ). The Membrane-Integrated Steric Chaperone Lif Facilitates Active Site Opening of Pseudomonas Aeruginosa Lipase A. J. Comput. Chem. 41 (6), 500–512
Not in our library10.1002/jcc.26085
181.
Viegas A. Dollinger P. Verma N. Kubiak J. Viennet T. Seidel C. A.. (2020 ). Structural and Dynamic Insights Revealing How Lipase Binding Domain MD1 of Pseudomonas Aeruginosa Foldase Affects Lipase Activation. Sci. Rep. 10 (1), 1–15
Not in our library10.1038/s41598-020-60093-4
182.
Wargo M. J. Gross M. J. Rajamani S. Allard J. L. Lundblad L. Allen G. B.. (2011 ). Hemolytic Phospholipase C Inhibition Protects Lung Function During Pseudomonas Aeruginosa Infection. Am. J. Respir. Crit. Care Med. 184 (3), 345
Not in our library10.1164/rccm.201103-0374oc
183.
Webster S. S. Lee C. K. Schmidt W. C. Wong G. O'Toole G. A. (2021 ). Interaction Between the Type 4 Pili Machinery and a Diguanylate Cyclase Fine-Tune C-Di-GMP Levels During Early Biofilm Formation. Proc. Natl. Acad. Sci. United States America 118 (26), e2105566118
Not in our library10.1073/pnas.2105566118
184.
Whitchurch C. B. Leech A. J. Young M. D. Kennedy D. Sargent J. L. Bertrand J. J.. (2004 ). Characterization of a Complex Chemosensory Signal Transduction System Which Controls Twitching Motility in Pseudomonas Aeruginosa. Mol. Microbiol. 52 (3), 873–893
Not in our library10.1111/j.1365-2958.2004.04026.x
185.
Wilson R. Sykes D. A. Watson D. Rutman A. Taylor G. W. Cole P. J. (1988 ). Measurement of Pseudomonas Aeruginosa Phenazine Pigments in Sputum and Assessment of Their Contribution to Sputum Sol Toxicity for Respiratory Epithelium. Infect Immun. 56 (9), 2515–2517
Not in our library10.1128/iai.56.9.2515-2517.1988
186.
Woo J. Hearne K. Kelson A. Yee L. Espadas C. Truong V. L (2019 ). “"716. In Vitro and In Vivo Nonclinical Efficacy of AR-501 (Gallium Citrate)",” in Open Forum Infectious Diseases. (Washington, D. C.:Oxford Academic) 6(Supplement_2), S322
Not in our library10.1093/ofid/ofz360.784
187.
World Health Organization (2017 ) WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed. Available at: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed May 7 2022).
Not in our library
188.
Wu M. Li X. (2015 ). “"Chapter 87 - Klebsiella Pneumoniae and Pseudomonas Aeruginosa,",” in Molecular Medical Microbiology (Second Edition). Eds. Tang Y.-W. Sussman M. Liu D. Poxton I. Schwartzman J. (Boston: Academic Press), 1547–1564
Not in our library10.1016/b978-0-12-397169-2.00087-1
189.
Wu H. Song Z. Hentzer M. Andersen J. B. Molin S. Givskov M.. (2004 ). Synthetic Furanones Inhibit Quorum-Sensing and Enhance Bacterial Clearance in Pseudomonas Aeruginosa Lung Infection in Mice. J. Antimicro Chemother 53 (6), 1054–1061
Not in our library10.1093/jac/dkh223
190.
Yaeger L. N. Coles V. E. Chan D. C. Burrows L. L. (2021 ). How to Kill Pseudomonas—emerging Therapies for a Challenging Pathogen. Ann. New York Acad. Sci. 1496 (1), 59–81
Not in our library10.1111/nyas.14596
191.
Yahr T. L. Goranson J. Frank D. W. (1996 ). Exoenzyme S of Pseudomonas Aeruginosa is Secreted by a Type III Pathway. Mol. Microbiol. 22 (5), 991–1003
Not in our library10.1046/j.1365-2958.1996.01554.x
192.
Yahr T. L. Vallis A. J. Hancock M. K. Barbieri J. T. Frank D. W. (1998 ). ExoY, an Adenylate Cyclase Secreted by the Pseudomonas Aeruginosa Type III System. Proc. Natl. Acad. Sci. 95 (23), 13899–13904
Not in our library10.1073/pnas.95.23.13899
193.
Zhang A. Veesenmeyer J. L. Hauser A. R. Payne S. M. (2018 ). Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas Aeruginosa Cytotoxin ExoU. Infect Immun. 86 (1), e00402–e00417
Not in our library10.1128/iai.00402-17
194.
Zhang Z. Zhang X. (2021 ). Evolution of Subfamily I.1 Lipases in Pseudomonas Aeruginosa. Curr. Microbiol. 78 (9), 3494–3504
Not in our library10.1007/s00284-021-02589-4

Cited by papers we hold 1

Biofilm and wound healing: from bench to bedside · 2023
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.